BEACOPP regimen: Difference between revisions

	WikiDoc Resources for BEACOPP regimen
Articles
Most recent articles on BEACOPP regimen Most cited articles on BEACOPP regimen Review articles on BEACOPP regimen Articles on BEACOPP regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on BEACOPP regimen Images of BEACOPP regimen Photos of BEACOPP regimen Podcasts & MP3s on BEACOPP regimen Videos on BEACOPP regimen
Evidence Based Medicine
Cochrane Collaboration on BEACOPP regimen Bandolier on BEACOPP regimen TRIP on BEACOPP regimen
Clinical Trials
Ongoing Trials on BEACOPP regimen at Clinical Trials.gov Trial results on BEACOPP regimen Clinical Trials on BEACOPP regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on BEACOPP regimen NICE Guidance on BEACOPP regimen NHS PRODIGY Guidance FDA on BEACOPP regimen CDC on BEACOPP regimen
Books
Books on BEACOPP regimen
News
BEACOPP regimen in the news Be alerted to news on BEACOPP regimen News trends on BEACOPP regimen
Commentary
Blogs on BEACOPP regimen
Definitions
Definitions of BEACOPP regimen
Patient Resources / Community
Patient resources on BEACOPP regimen Discussion groups on BEACOPP regimen Patient Handouts on BEACOPP regimen Directions to Hospitals Treating BEACOPP regimen Risk calculators and risk factors for BEACOPP regimen
Healthcare Provider Resources
Symptoms of BEACOPP regimen Causes & Risk Factors for BEACOPP regimen Diagnostic studies for BEACOPP regimen Treatment of BEACOPP regimen
Continuing Medical Education (CME)
CME Programs on BEACOPP regimen
International
BEACOPP regimen en Espanol BEACOPP regimen en Francais
Business
BEACOPP regimen in the Marketplace Patents on BEACOPP regimen
Experimental / Informatics
List of terms related to BEACOPP regimen

← Older edit

VisualWikitext

Latest revision as of 14:18, 11 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: BEACOPP; BEACOPP Regimen; BEACOPP regimen; Bleomycin-Etoposide-Adriamycin-Cyclophosphamide-Oncovin-Procarbazine-Prednisone Regimen; Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Procarbazine/Vincristine

Overview

BEACOPP regimen refers to an a chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.^[1]^[2]

Regimen

BBleomycin

EEtoposide

ADoxorubicin (Adriamycin)

CCyclophosphamide

OVincristine (Oncovin)

PProcarbazine

PPrednisone

Indications

Advanced-stage Hodgkin lymphoma ^[3]

References

↑ "NCI Thesaurus".
↑ "R-CHOP - National Cancer Institute".
↑ Cheson BD (2014). "Which Hodgkin's patients in the Unites States should be treated with BEACOPP?". Curr Hematol Malig Rep. 9 (3): 222–6. doi:10.1007/s11899-014-0213-6. PMID 24879421.

[1] "NCI Thesaurus".

[2] "R-CHOP - National Cancer Institute".

[pmid24879421-3] Cheson BD (2014). "Which Hodgkin's patients in the Unites States should be treated with BEACOPP?". Curr Hematol Malig Rep. 9 (3): 222–6. doi:10.1007/s11899-014-0213-6. PMID 24879421.

[1]

[2]

[3]

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AV}}
-{{SK}} Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
+{{SK}} BEACOPP; BEACOPP Regimen; BEACOPP regimen; Bleomycin-Etoposide-Adriamycin-Cyclophosphamide-Oncovin-Procarbazine-Prednisone Regimen; Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Procarbazine/Vincristine
 ==Overview==
-{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
+{{PAGENAME}} refers to an a chemotherapy regimen consisting of [[bleomycin]], [[etoposide]], [[doxorubicin|doxorubicin hydrochloride (Adriamycin)]], [[cyclophosphamide]], [[vincristine|vincristine (Oncovin)]], [[procarbazine]] and [[prednisone]], used for the treatment of [[Hodgkin's lymphoma|advanced-stage Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
 ==Regimen==
-[[Rituximab|{{button|R – Rituximab}}]]
+{{chemo|B|Bleomycin}}
-[[Cyclophosphamide|{{button|C – Cyclophosphamide}}]]
+{{chemo|E|Etoposide}}
-[[Doxorubicin|{{button|H – Doxorubicin (Hydroxydaunomycin)}}]]
+{{chemo|A|Doxorubicin (Adriamycin)}}
-[[Vincristine|{{button|O – Vincristine (Oncovin)}}]]
+{{chemo|C|Cyclophosphamide}}
-[[Prednisone|{{button|P – Prednisone}}]]
+{{chemo|O|Vincristine (Oncovin)}}
+{{chemo|P|Procarbazine}}
+{{chemo|P|Prednisone}}
 ==Indications==
-* [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref>
+* [[Hodgkin lymphoma|Advanced-stage Hodgkin lymphoma]] <ref name="pmid24879421">{{cite journal| author=Cheson BD| title=Which Hodgkin's patients in the Unites States should be treated with BEACOPP? | journal=Curr Hematol Malig Rep | year= 2014 | volume= 9 | issue= 3 | pages= 222-6 | pmid=24879421 | doi=10.1007/s11899-014-0213-6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24879421  }} </ref>
-* [[Mantle cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa1200920 | issn = 1533-4406 | volume = 367 | issue = 6 | pages = 520–531 | last = Kluin-Nelemans | first = H. C. | coauthors = E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling | title = Treatment of older patients with mantle-cell lymphoma | journal = The New England Journal of Medicine | date = 2012-08-09 | pmid = 22873532 }}</ref>
 ==References==